

## **Biologic Therapeutic Drugs: Technologies and Global Markets**

Market Research Report | 2024-01-24 | 253 pages | BCC Research

### **AVAILABLE LICENSES:**

- Single User License \$5500.00
- 2-5 Users License \$6600.00
- Site License \$7920.00
- Enterprise License \$9504.00

### **Report description:**

Description

Report Scope:

The current report offers a detailed picture of the biologics market.

This report highlights the current and future market potential for biologics and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities and trends in the market. The report also covers market projections through 2028, as well as key market players.

This report details market shares for biologics based on product, source, application and geography. Based on product, the market is segmented into therapeutic proteins, cell and gene therapy, vaccines, and other segments. Based on application, the market is segmented into cancer, autoimmune conditions, aesthetics, eye disorders, and others. Based on source, the market is segmented into human, animal, micro-organism, fermented cell and others

Based on geography, the market has been segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. Detailed analyses of major countries (the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China and India) are covered in regional segments. For market estimates, data has been provided for 2022 as the base year, with forecasts for 2023 through 2028. Estimated values are based on product manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.

Report Includes:

- 38 data tables and 59 additional tables

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scott's-international.com](mailto:support@scott's-international.com)

[www.scott's-international.com](http://www.scott's-international.com)

- An overview of the global markets for biologic therapeutic drugs.
- Analyses of the global market trends, with historical market revenue data (sales figures) from 2021 to 2022, estimates for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028.
- Estimate of the actual market size and revenue forecast, and a corresponding market share analysis by product type, therapeutic area and region.
- A discussion of the market's opportunities and challenges, as well as emerging technologies and regulations.
- Overview of the sustainability trends, with emphasis on consumer attitudes, companies' ESG scores, the future of ESG, case studies and the ESG practices of companies.
- A discussion of the technological means that the leading biopharmaceutical companies are using.
- Evaluation of the ongoing clinical trials and R&D activity for biologics production.
- A look at the key drugs on the market and recent approvals, sales statistics and past performance of the top selling biologics, as well as their patent expiries.
- Review of emerging technologies and patents.
- An overview of the competitive landscape, including a look at the major vendors' market shares, recent M&A activity, and venture funding outlook.
- Company profiles of major players within the industry, including Amgen Inc., Abbvie Inc., Eli Lilly And Co., Novartis Ag, and Glaxosmithkline Plc

## Executive Summary

### Summary:

The global market for biologic therapeutic drugs was valued at \$REDACTED billion in 2022. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED% to reach \$REDACTED billion by 2028. The growth of the global market is attributed to the rising prevalence of chronic and acute diseases and the growing level of advancement in biologics production.

The global biologic therapeutic drug market is segmented in this report by product, application, source and region.

### Reasons for Doing This Study:

The biologics market is wide-ranging and has important implications for the future of medicine and industry advancement. For companies with an effective strategy, market opportunities await. Importantly, the ability to develop an effective strategy begins where opportunity exists and ends with how to effectively execute a plan to capture profit from such opportunities.

Market growth has been spurred by the need for a more extensive pipeline from drug companies, attractive targets against challenging diseases, a push by companies to pursue biosimilars (a biologic like another biologic that has already been authorized for use) and manufacturing technologies that reduce the cost to produce profitable products.

This report seeks to address the critically important topics of changing market dynamics, emerging players and technologies, strategies for accessing emerging markets, and specific disease segments and geographies to allocate resources and make effective decisions.

## Table of Contents:

- Table of Contents
- Chapter 1 Introduction
- Introduction
- Study Goals and Objectives

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Reasons for Doing This Study  
Scope of Report  
What's New in this Update?  
Methodology  
Information Sources  
Geographic Breakdown  
Segmentation Breakdown  
Chapter 2 Summary and Highlights  
Market Overview  
Chapter 3 Market and Technology Background  
Biopharmaceutical Industry Structure  
Origins of Biotechnology  
Involvement of Large Pharmaceutical Companies  
Overview of Biologics  
Biologics Manufacturing  
Biopharmaceutical Manufacturing Process  
The Preparation Process  
Expression Systems for Therapeutic Protein Production  
Advantages of E. coli for Microbial Production  
Mammalian Cell Therapeutic Protein Production  
FDA Regulation of Biologics  
Chapter 4 Market Dynamics  
Market Drivers  
Overview  
Rising Prevalence of Chronic Diseases  
Advancement in Biologics  
Development in Cell and Gene Therapy Methodology  
Increase in Infectious and Chronic Diseases  
Market Restraints  
Emergence of Biosimilars  
Expensive Cost of Biologics  
Market Opportunities  
Opportunities in Emerging Nations  
Chapter 5 Market Breakdown by Product Segment  
Global Market for Biological Therapeutic Drugs by Product  
Therapeutic Proteins  
Vaccines  
Cell and Gene Therapy  
Others  
Chapter 6 Market Breakdown by Application  
Global Market for Biological Therapeutic Drugs by Application  
Cancer  
Autoimmune Conditions  
Aesthetics  
Eye Disorder  
Others  
Chapter 7 Market Breakdown by Source

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Global Market for Biological Therapeutic Drugs by Source

Human

Animal

Microorganisms

Fermented Cells

Other Sources

Chapter 8 Market Breakdown by Region

Global Market for Biological Therapeutic Drugs by Region

North America

Europe

Asia-Pacific

Rest of World

GCC Countries

Brazil

Rest of World Countries

Chapter 9 Emerging Technology for Biologics Manufacturing

Introduction

AcceTT & BacSec Technologies

Single-use Technologies

Cell and Gene Therapy (CGT)

Doggybone DNA (dbDNA)

Animal Plasma Isolation

Hybridoma Generation

B Cell Screening

Display Technologies

Emerging Biologics Discovery and Generation Technologies

Emerging Trends in Biologic Production Technologies

Example of New Developments by Companies

Samsung Biologics

AstraZeneca

Genentech Inc. (Member of Roche family)

Chapter 10 Sustainability in the Biopharmaceuticals and Biologics Industry: An ESG Perspective

Importance of ESG in the Biopharmaceuticals Manufacturing Industry

ESG Ratings and Metrics: Understanding the Data

ESG Practices in the Biopharmaceuticals and Biologics Manufacturing Industry

BCC Research Viewpoint

Chapter 11 M&A and Venture Funding Outlook

M&A Analysis

M&A Deals 2018-2023

Top Biologic Drug Startups

Flourishing Biotech Startups (2023)

Chapter 12 FDA Approved Monoclonal Antibodies, 1986-2023

Chapter 13 Competitive Landscape

Porter's Five Forces Analysis

Bargaining Power of Suppliers

Bargaining Power of Buyers

Threat of New Entrants

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Threat of Substitutes  
Competitive Rivalry/Degree of Competition  
Chapter 14 Company Profiles  
ABBVIE INC.  
AMGEN INC.  
BAXTER INTERNATIONAL INC.  
BOEHRINGER INGELHEIM INTERNATIONAL GMBH  
CSL LTD.  
DENDREON PHARMACEUTICALS LLC.  
ELI LILLY AND CO.  
F. HOFFMANN-LA ROCHE LTD.  
GLAXOSMITHKLINE PLC  
GLYCOTOPE GMBH  
GRIFOLS S.A.  
JSC PHARMSTANDARD  
KEDRION S.P.A.  
LONZA  
MERCK & CO. INC.  
NOVARTIS AG  
OCTAPHARMA AG  
RELIANCE LIFE SCIENCES  
SANOFI  
TEVA PHARMACEUTICAL INDUSTRIES LTD.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Biologic Therapeutic Drugs: Technologies and Global Markets**

Market Research Report | 2024-01-24 | 253 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$5500.00
	2-5 Users License	\$6600.00
	Site License	\$7920.00
	Enterprise License	\$9504.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-04"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

